TVTX Share Price Performance
US$29.69
13.13 (79.29%)
29.9% undervalued intrinsic discount
US$42.36
Fair Value
Price US$29.69
AnalystConsensusTarget US$42.36
AnalystHighTarget US$49.00
AnalystLowTarget US$32.41
Fair ValueUS$42.36
Share Pricen/a
Travere Therapeutics, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 41 Fair Values set on narratives written by author
TVTX Community Narratives
AN
Fair Value US$42.36 28.1% undervalued intrinsic discount
TVTX: Recent Regulatory Momentum Will Drive FSGS And IgAN Market Leadership
0users have liked this narrative
0users have commented on this narrative
17users have followed this narrative
AN
Fair Value US$49 37.9% undervalued intrinsic discount
FILSPARI Expansion And Aging Trends Will Advance Precision Therapies
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value US$32.41 6.1% undervalued intrinsic discount
Regulatory Pressures And Competition Will Hamper Uptake But Hope Endures
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
FILSPARI Expansion And Aging Trends Will Advance Precision Therapies
Key Takeaways Rapid market adoption, limited competition, and clinical leadership uniquely position Travere to achieve dominance and pricing power in rare kidney disease therapies. Strong operational execution and favorable industry trends support robust revenue growth, superior margins, and a resilient, cash-generative business model.Read more
38
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$49
37.9% undervalued intrinsic discount
Fair Value
Profit Margin
39.3%
Future PE
10.8x
Price in 2029
US$60.25
TVTX: Recent Regulatory Momentum Will Drive FSGS And IgAN Market Leadership
Key Takeaways FILSPARI's expanding use and recognition in rare kidney diseases positions Travere for first-mover advantage, sustained growth, and meaningful gains in underserved markets. Strong financial discipline, increasing recurring revenue, and efficient regulatory progress provide resources for pipeline advancement and future commercial launches.Read more
265
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
17users have followed this narrative
AN
US$42.36
28.1% undervalued intrinsic discount
Fair Value
Profit Margin
28.72%
Future PE
16.49x
Price in 2029
US$51.96
Regulatory Pressures And Competition Will Hamper Uptake But Hope Endures
Key Takeaways Heavy reliance on FILSPARI and persistent net losses create vulnerability to competition, regulatory changes, and setbacks in new product development. Increasing R&D expenses and pricing pressures from government controls threaten margins, limiting sustainable growth and financial flexibility despite favorable market trends.Read more
26
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$32.41
6.1% undervalued intrinsic discount
Fair Value
Profit Margin
18.33%
Future PE
23.23x
Price in 2029
US$39.64
Trending Discussion
Recently Updated Narratives
AN
TVTX: Extended Review And 90 Day Catalyst Watch Will Support Bullish Repricing
Fair Value: US$49 37.9% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
TVTX: FSGS Regulatory Extension And Kidney Data Will Drive A Constructive Outlook
Fair Value: US$42.36 28.1% undervalued intrinsic discount
17 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
TVTX: PDUFA Extension And Regulatory Clarity Will Shape Balanced Risk Profile
Fair Value: US$32.41 6.1% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Travere Therapeutics, Inc. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -0.54
- 55.91%
- -10.24%
- 271.5%
About TVTX
- Founded
- n/a
- Employees
- 497
- CEO
- WebsiteView website
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company’s products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase, a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. Travere Therapeutics, Inc. was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. The company is headquartered in San Diego, California.
